The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy

PurposeTo develop a novel criterion based on the response evaluation criteria in solid tumors (RECIST) 1.1 and alpha fetoprotein (AFP) and evaluate its performance in tumor response for patients with unresectable hepatocellular carcinoma (uHCC) receiving conversion-radiotherapy before hepatectomy.Me...

Full description

Bibliographic Details
Main Authors: Ying Xu, Yi Yang, Lu Li, Feng Ye, Xinming Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
radiotherapy
hepatectomy
tumor response
RECIST 1.1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.905260/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.905260/full

Similar Items